GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyloris Pharmaceuticals SA (LTS:0AB6) » Definitions » Gross Profit

Hyloris Pharmaceuticals (LTS:0AB6) Gross Profit : €2.72 Mil (TTM As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Hyloris Pharmaceuticals Gross Profit?

Hyloris Pharmaceuticals's gross profit for the six months ended in Dec. 2023 was €1.61 Mil. Hyloris Pharmaceuticals's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was €2.72 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Hyloris Pharmaceuticals's gross profit for the six months ended in Dec. 2023 was €1.61 Mil. Hyloris Pharmaceuticals's Revenue for the six months ended in Dec. 2023 was €1.65 Mil. Therefore, Hyloris Pharmaceuticals's Gross Margin % for the quarter that ended in Dec. 2023 was 97.16%.

Hyloris Pharmaceuticals had a gross margin of 97.16% for the quarter that ended in Dec. 2023 => Durable competitive advantage

During the past 8 years, the highest Gross Margin % of Hyloris Pharmaceuticals was 96.81%. The lowest was 17.14%. And the median was 55.40%.


Hyloris Pharmaceuticals Gross Profit Historical Data

The historical data trend for Hyloris Pharmaceuticals's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyloris Pharmaceuticals Gross Profit Chart

Hyloris Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial 0.03 0.03 2.99 2.86 2.72

Hyloris Pharmaceuticals Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.19 0.97 1.89 1.11 1.61

Competitive Comparison of Hyloris Pharmaceuticals's Gross Profit

For the Biotechnology subindustry, Hyloris Pharmaceuticals's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hyloris Pharmaceuticals's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hyloris Pharmaceuticals's Gross Profit distribution charts can be found below:

* The bar in red indicates where Hyloris Pharmaceuticals's Gross Profit falls into.



Hyloris Pharmaceuticals Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Hyloris Pharmaceuticals's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=2.814 - 0.093
=2.72

Hyloris Pharmaceuticals's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=1.654 - 0.047
=1.61

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €2.72 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Hyloris Pharmaceuticals's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=1.61 / 1.654
=97.16 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Hyloris Pharmaceuticals  (LTS:0AB6) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Hyloris Pharmaceuticals had a gross margin of 97.16% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Hyloris Pharmaceuticals Gross Profit Related Terms

Thank you for viewing the detailed overview of Hyloris Pharmaceuticals's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Hyloris Pharmaceuticals (LTS:0AB6) Business Description

Traded in Other Exchanges
Address
Boulevard Patience et Beaujonc N°3/1, Liege, BEL, 4000
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans these areas such as Cardiovascular, Other Reformulations, and Established markets (high-barrier generics). It has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a non-opioid analgesic product for the treatment of pain.

Hyloris Pharmaceuticals (LTS:0AB6) Headlines

No Headlines